Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Canaccord Genuity Downgrades Nevro to Hold, Announces $112 Price Target

Canaccord Genuity analyst William Plovanic downgrades Nevro (NYSE:NVRO) from Buy to Hold and announces $112 price target.

August 5, 2021

1 minute read

Canaccord Genuity analyst William Plovanic downgrades Nevro (NYSE:NVRO) from Buy to Hold and announces $112 price target.

$1000 Invested In This Stock 20 Years Ago Would Be Worth $6,000 Today

Today, 11:24 PM

Enbridge (NYSE:ENB) has outperformed the market over the past 20 years by 1.15% on an annualized basis producing…

Today, 11:24 PM

-Dow Jones

Today, 11:24 PM

Raymond James analyst Joseph Altobello upgrades Xponential Fitness (NYSE:XPOF) from Market Perform to Strong Buy and announces $14 price target.

Today, 11:24 PM

Morgan Stanley analyst Drew Ranieri maintains Baxter Intl (NYSE:BAX) with a Overweight and lowers the price target from $72 to $70.